Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Stripped Heart Matrix Supports Growth of Rejection-Free Replacement Organ

By LabMedica International staff writers
Posted on 21 Mar 2016
A team of bioengineers used a decellularized heart matrix as scaffolding to rebuild the organ for transplantation without immune markers that would prime the organ for rejection.

Investigators at Massachusetts General Hospital (Boston, USA) had demonstrated the feasibility of this approach using rat hearts. More...
In the current study, they sought to upscale the method to accommodate human hearts.

The procedure involved stripping cellular components from donor hearts that had been found to be unsuitable for transplantation. The remaining extracellular matrix scaffold, which did not contain any immune markers, could then be seeded with organ-appropriate cell types. To prevent rejection by the potential recipient of the organ, seed cardiomyocytes were derived from induced pluripotent stem cells (iPSCs) that had been generated from the patient's skin cells.

The investigators repopulated the native human cardiac matrix with stem-cell derived cardiomyocytes and generated tissues of increasing three-dimensional complexity. They maintained such cardiac tissue constructs in culture for 120 days to demonstrate definitive sarcomeric structure, cell and matrix deformation, contractile force, and electrical conduction. Under culture conditions that mimicked those within the human body, the seeded constructs developed force-generating myocardial tissue and showed electrical conductivity, left ventricular pressure development, and metabolic function.

Summarizing their results in the January 8, 2016, issue of the journal Circulation Research, the investigators stated that native cardiac extracellular matrix scaffolds maintained matrix components and structure to support the seeding and engraftment of human iPSCs–derived cardiomyocytes and enabled the bioengineering of functional human myocardial-like tissue of multiple complexities.

"Generating functional cardiac tissue involves meeting several challenges," said first author Dr. Jacques Guyette, a postdoctoral research fellow at Massachusetts General Hospital. "These include providing a structural scaffold that is able to support cardiac function, a supply of specialized cardiac cells, and a supportive environment in which cells can repopulate the scaffold to form mature tissue capable of handling complex cardiac functions."

"Regenerating a whole heart is most certainly a long-term goal that is several years away, so we are currently working on engineering a functional myocardial patch that could replace cardiac tissue damaged due a heart attack or heart failure," said Dr. Guyette. "Among the next steps that we are pursuing are improving methods to generate even more cardiac cells—recellularizing a whole heart would take tens of billions—optimizing bioreactor-based culture techniques to improve the maturation and function of engineered cardiac tissue, and electronically integrating regenerated tissue to function within the recipient's heart."

Related Links:

Massachusetts General Hospital



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.